Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Li (Manchester, United Kingdom), J. Baker (Manchester, United Kingdom), C. Murray (Manchester, United Kingdom), N. Cooper (Manchester, United Kingdom), C. Lucas (Manchester, United Kingdom), D. Singh (Manchester, United Kingdom), S. Lea (Manchester, United Kingdom). The modulatory effects of Nrf2 activators in a pulmonary arterial hypertension model. 3562

Member's Comments

No comment yet.

Related content which might interest you: Dysregulation of TGF-β/BMP signaling in a monocrotaline model of pulmonary hypertension Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Additive protective effects of sacubitril/valsartan and bosentan on vascular remodeling in experimental pulmonary hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension Year: 2007 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 The pathophysiological role of novel pulmonary arterial hypertension gene SOX17 Source: Eur Respir J, 58 (3) 2004172; 10.1183/13993003.04172-2020 Year: 2021 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Leptin signalling system as a target for pulmonary arterial hypertension therapy Source: Eur Respir J 2015; 45: 1066-1080 Year: 2015 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 A central role for nuclear factor of activated T cells (NFAT) in human pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020